clinical trial · NCT06118866
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
Hope Medicine (Nanjing) Co., Ltd·phase2·completed·n = 192
Androgenetic Alopeciaplacebo-Q2WHMI-115-120mg-Q4WHMI-115-240mg-Q4WHMI-115, 240mg-Q2W
brief summary
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
started
Sep 11, 2023
primary completion
Aug 26, 2024
completion
Nov 28, 2024
last updated
Jun 4, 2025
official title
A Randomized, Multicenter, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy in Male Androgenetic Alopecia Treated With HMI-115 Over a 24-Week Treatment Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol